Philips launches image-guided neurology surgical tech in Europe

Philips Healthcare's NeuroSuite-Courtesy of Philips

At the Live Interventional Neuroradiology & Neurosurgery Course in Paris, Philips Healthcare ($PHG) launched a new device, the NeuroSuite, for minimally invasive image guided neurological surgeries for patients with ailments like ischemic stroke or large neck aneurysm.

The company says the new product's advantages include a lower X-ray dose and real-time 3D imaging. 

"In image-guided interventions the ultimate goal is to see clearly and navigate effectively, while managing X-ray dose for patients, staff and clinicians," said Ronald Tabaksblat, Philip's general manager of the interventional X-ray division. "Developed in collaboration with clinical partners around the world, Philips NeuroSuite has been designed for that purpose and underpins Philips' global leadership position in live-image guidance technologies."

Philips said in the statement that the first NeuroSuite system was installed in Kaolinksa University Hospital in Stockholm, Sweden, which the company described as a "center of excellence for stroke treatment." 

"Philips' latest innovation is NeuroSuite with a new 20 inch detector on the frontal plane, providing superb 3D-images and big enough for spine imaging. On the lateral plane, the new 15 inch detector brings visualization of the complete cerebral vasculature, with reduced collision risks and enhanced projection freedom," said Dr. Michael SAderman of the hospital's department of neuroradiology.

The NeuroSuite is not available in the U.S.

- read the release

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.